|
 The FDA is now expected to decide on Sustol by late February instead
of the earlier deadline of Sunday, Heron said on Friday.
Sustol succeeded in a late-stage study that tested the drug against
GlaxoSmithKline Plc's anti-nausea drug, Zofran. Both the drugs were
tested in combination with two standard-of-care nausea treatments.
Chemotherapy-induced nausea and vomiting (CINV), considered one of
the most acute side effects of cancer therapy, occurs in up to 80
percent of patients, according to the National Institute of Health.
Heron is testing another drug for CINV. The company has two other
experimental drugs aimed at treating chronic pain.
The Redwood City, California-based company's shares closed at $23.22
on Thursday.
(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Savio
D'Souza and Kirti Pandey)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
